Table 1 Patient and Tumour Characteristics.
From: Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition
AGE | MEAN | RANGE |
|---|---|---|
43.8 | 19 - 77 | |
HISTOLOGICAL SUBTYPE | NUMBER | % |
Infiltrating duct carcinoma, NOS | 190 | 80.2 |
Carcinoma, NOS | 16 | 6.8 |
Lobular carcinoma, NOS | 10 | 4.2 |
Infiltrating duct and lobular carcinoma | 8 | 3.4 |
Medullary carcinoma, NOS | 5 | 2.1 |
Others | 8 | 3.4 |
GRADE | ||
1 | 24 | 10.1 |
2 | 67 | 28.3 |
3 | 123 | 51.9 |
No grade | 23 | 9.7 |
NODAL STATUS | ||
N0 | 96 | 40.5 |
N1 (1-3) | 37 | 15.6 |
N2 (4-9) | 13 | 5.5 |
N3 (10 or >) | 6 | 2.5 |
Not known | 85 | 35.9 |
GERMLINE BRCA1/2, CHEK2, PALB2 STATUS | ||
BRCA1 | 103 | 43.5 |
BRCA2 | 48 | 20.3 |
PALB2 | 4 | 1.7 |
CHEK2 | 2 | 0.8 |
Wildtype | 80 | 33.8 |
BASAL-LIKE CLASSIFICATION | ||
BLBC (CK5/CK14 and /or EGFR) Positive | 76 | 32.1 |
NBLBC (CK5/14 and EGFR) Negative | 136 | 57.4 |
Unclassified | 25 | 10.5 |
ER/PR/HER2 STATUS | ||
ER/PR Positive, HER2 Negative | 88 | 37.1 |
ER/PR Positive, HER2 Positive | 33 | 13.9 |
ER/PR Negative, HER2 Positive | 18 | 7.62 |
Triple Negative | 75 | 31.6 |
Not tested | 23 | 9.7 |
PROGRESSION-FREE SURVIVAL (ALL CASES) | Events | Median Months |
64 | 161.1 | |
PROGRESSION-FREE SURVIVAL (BRCA1 MUTANT) | Events | Median Months |
28 | 165.5 | |
OVERALL SURVIVAL (ALL CASES) | Events | Median Months |
60 | 165.2 | |
OVERALL SURVIVAL (BRCA1 MUTANT) | Events | Median Months |
26 | 166.4 | |
